What this pack is
CATAPRES / clonidine oral is the brand name in this record; clonidine hydrochloride immediate-release tablets is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
CATAPRES / clonidine oralGeneric nameclonidine hydrochloride immediate-release tablets
How this medicine works
The FDA label says clonidine stimulates brainstem alpha-adrenoreceptors, reduces central sympathetic outflow, and can lower peripheral resistance, heart rate and blood pressure. This helps explain somnolence, hypotension, bradycardia and rebound after abrupt withdrawal, but cannot predict an individual's response or calculate tablet count, frequency, taper or formulation conversion.
Read source: United States ↗reviewed 2026-09-02More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- CATAPRES / clonidine oral
- Source-scoped market brand names
- CATAPRES · United StatesHistorical regulator record ↗Historical originator/RLD under NDA 017407. The 0.1, 0.2 and 0.3 mg immediate-release oral tablets are DISCN and marked as not withdrawn for safety or effectiveness. This page does not display a historical original-brand pack.
- clonidine hydrochloride tablets · United StatesCurrent regulator record ↗Current TruPharma generic label under ANDA 070923: one 0.05 mg bottle and three bottle counts each for 0.1, 0.2 and 0.3 mg. A regulatory label is not live stock.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- clonidine hydrochloride immediate-release tablets
- Dosage-form class
- Clonidine hydrochloride immediate-release oral tablets. Products outside this package identity include CATAPRES-TTS transdermal systems, DURACLON injection, KAPVAY/JENLOGA/NEXICLON XR extended-release products, JAVADIN oral solution, the COMBIPRES fixed combination and other clonidine-containing products. A shared generic name or milligram figure does not establish formulation conversion, frequency, tapering, splitting or substitution.
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
10 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.05 mg clonidine hydrochloride per tablet; 100-tablet bottle
- Product code
- NDC 52817-183-10
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.05 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 100 tablets per bottle
- Labelled appearance
- yellow · oval immediate-release tablet · imprint 05Single score-line appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.1 mg clonidine hydrochloride per tablet; 100-tablet bottle
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 52817-180-10
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.1 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 100 tablets per bottle
- Labelled appearance
- yellow · round immediate-release tablet · imprint MP;657Single score-line appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.1 mg clonidine hydrochloride per tablet; 500-tablet bottle
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 52817-180-50
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.1 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 500 tablets per bottle
- Labelled appearance
- yellow · round immediate-release tablet · imprint MP;657Single score-line appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.1 mg clonidine hydrochloride per tablet; 1000-tablet bottle
- Product code
- NDC 52817-180-00
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.1 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 1000 tablets per bottle
- Labelled appearance
- yellow · round immediate-release tablet · imprint MP;657Single score-line appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.2 mg clonidine hydrochloride per tablet; 100-tablet bottle
- Product code
- NDC 52817-181-10
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.2 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 100 tablets per bottle
- Labelled appearance
- white · round immediate-release tablet · imprint MP;658Single score-line appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.2 mg clonidine hydrochloride per tablet; 500-tablet bottle
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 52817-181-50
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.2 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 500 tablets per bottle
- Labelled appearance
- white · round immediate-release tablet · imprint MP;658Single score-line appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.2 mg clonidine hydrochloride per tablet; 1000-tablet bottle
- Product code
- NDC 52817-181-00
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.2 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 1000 tablets per bottle
- Labelled appearance
- white · round immediate-release tablet · imprint MP;658Single score-line appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.3 mg clonidine hydrochloride per tablet; 100-tablet bottle
- Product code
- NDC 52817-182-10
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.3 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 100 tablets per bottle
- Labelled appearance
- green · round immediate-release tablet · imprint MP;659Single score-line appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.3 mg clonidine hydrochloride per tablet; 500-tablet bottle
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 52817-182-50
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.3 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 500 tablets per bottle
- Labelled appearance
- green · round immediate-release tablet · imprint MP;659Single score-line appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (SPL v11; effective 30 Apr 2026)
0.3 mg clonidine hydrochloride per tablet; 1000-tablet bottle
- Product code
- NDC 52817-182-00
- Form and route
- clonidine hydrochloride immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- clonidine hydrochloride
- 0.3 mglabelled amount per tablet; not an individual's tablet count, frequency, taper step or conversion to a CATAPRES-TTS patch, extended-release tablet, oral solution, injection or combination tablet
- Package
- 1000 tablets per bottle
- Labelled appearance
- green · round immediate-release tablet · imprint MP;659Single score-line appearance clue; not permission to split it yourself
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
Clonidine enlarged label: per-tablet mg, bottle count, somnolence/falls and rebound after abrupt withdrawal
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The 0.05, 0.1, 0.2 and 0.3 mg figures are amounts per tablet; 100, 500 and 1000 Tablets are bottle counts. The current tablets are scored, but a score is an exact-product appearance clue and does not automatically permit splitting. The site does not turn professional dose or withdrawal text into an individual's frequency, tablet count, taper steps or missed-dose plan.
- Somnolence, sedation, fatigue, dizziness, dry mouth and constipation are common. Older adults, night-time rising or co-use of sedating/blood-pressure medicines requires priority review of alertness, gait, orthostatic pressure and falls. Severe somnolence, fainting, injury or altered awareness needs local emergency care.
- Bradycardia, conduction abnormalities and hypotension require review with pulse, symptoms and the complete medicine list. If a beta blocker, digoxin, verapamil, diltiazem or another heart-rate/blood-pressure medicine is also present, do not self-space, adjust or choose one to stop first.
- Abrupt clonidine withdrawal can cause a rapid pressure rise, headache, nervousness or agitation and tremor; rare severe events can be life-threatening. Risk needs particular attention at higher doses or with a beta blocker. Do not abruptly stop from a webpage or ask it to generate a taper schedule.
- Vomiting, inability to eat or drink, missed medicine, hospital admission, surgery or an empty pack requires prompt contact with the prescriber or pharmacist about continuity. The site cannot calculate catch-up use, a substitute formulation or a temporary plan.
- Alcohol, sleep medicines, opioids, anxiolytics, sedating antihistamines or other CNS depressants can add somnolence and impaired reactions. Confirm individual response under the label and professional advice before driving, operating machinery or walking alone at night; the site cannot issue a 'safe' permission.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-02
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. generic clonidine hydrochloride 0.05/0.1/0.2/0.3 mg label, ten bottle NDCs and six exact package panels (ANDA 070923; Apr 2026) ↗Current regulatory record · reviewed 2026-09-02
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-09-02FDA: historical CATAPRES (clonidine hydrochloride) immediate-release oral-tablet label under NDA 017407 (2009 version) ↗reviewed 2026-09-02
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about CATAPRES / clonidine oral (clonidine hydrochloride immediate-release tablets). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
CATAPRES / clonidine oral is the brand in this record and clonidine hydrochloride immediate-release tablets is the active-ingredient name. Check both with the dosage form (Clonidine hydrochloride immediate-release oral tablets. Products outside this package identity include CATAPRES-TTS transdermal systems, DURACLON injection, KAPVAY/JENLOGA/NEXICLON XR extended-release products, JAVADIN oral solution, the COMBIPRES fixed combination and other clonidine-containing products. A shared generic name or milligram figure does not establish formulation conversion, frequency, tapering, splitting or substitution.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. generic clonidine hydrochloride 0.05/0.1/0.2/0.3 mg label, ten bottle NDCs and six exact package panels (ANDA 070923; Apr 2026) ↗Current regulatory record · reviewed 2026-09-02
- FDA: historical CATAPRES (clonidine hydrochloride) immediate-release oral-tablet label under NDA 017407 (2009 version) ↗reviewed 2026-09-02
HOW IT WORKS · NOT A TREATMENT PLAN
How clonidine affects blood pressure: brainstem alpha-adrenoreceptors and reduced sympathetic outflow
- Immediate-release tablets, patches, extended-release tablets, oral solution and injection can all contain clonidine yet differ in release, strength basis and use. A shared generic name or milligram figure does not permit self-conversion, assembly or substitution.
- A shared effect on pressure or heart rate does not permit self-combining clonidine with a beta blocker, certain calcium-channel blockers, digoxin or another antihypertensive. Review the complete list, pulse, pressure and symptoms together.
- Mechanism cannot decide who should use clonidine or infer an increase, decrease or stop from one home pressure reading. The site only helps identify the exact product, source and label boundary.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. generic clonidine hydrochloride 0.05/0.1/0.2/0.3 mg label, ten bottle NDCs and six exact package panels (ANDA 070923; Apr 2026) ↗Current regulatory record · reviewed 2026-09-02
- FDA: historical CATAPRES (clonidine hydrochloride) immediate-release oral-tablet label under NDA 017407 (2009 version) ↗reviewed 2026-09-02
- FDA: 1974 approval, RLD identity and dosage-form history for CATAPRES immediate-release oral tablets under NDA 017407 (NDA 022331 review) ↗reviewed 2026-09-02
SOURCE-TRACEABLE ARCHIVE
CATAPRES / clonidine oralclonidine hydrochloride immediate-release tablets
This page includes an exact current U.S. public-label package panel for CATAPRES / clonidine oral, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
U.S. approval of CATAPRES immediate-release oral tablets
FDA review records CATAPRES NDA 017407 as clonidine hydrochloride immediate-release oral tablets approved in Sep 1974 and identifies it as the RLD.
FDA: 1974 approval, RLD identity and dosage-form history for CATAPRES immediate-release oral tablets under NDA 017407 (NDA 022331 review) ↗Historical FDA CATAPRES label version
FDA preserves a label for CATAPRES 0.1, 0.2 and 0.3 mg oral tablets. It supports history and safety tracing and does not establish current brand supply.
FDA: historical CATAPRES (clonidine hydrochloride) immediate-release oral-tablet label under NDA 017407 (2009 version) ↗Current TruPharma generic label became effective
The current label under ANDA 070923 lists four per-tablet strengths, ten bottle NDCs and six exact package panels.
DailyMed (NLM): current U.S. generic clonidine hydrochloride 0.05/0.1/0.2/0.3 mg label, ten bottle NDCs and six exact package panels (ANDA 070923; Apr 2026) ↗
MARKET SCOPE
Market-record boundary
United States — CATAPRES immediate-release oral tablets
Historical originator/RLD; discontinuedNDA 017407; the 0.1, 0.2 and 0.3 mg rows are DISCN and not withdrawn for safety or effectiveness.
United States — current generic
Current public generic labelANDA 070923; 0.05/0.1/0.2/0.3 mg across ten bottle NDCs. A regulatory label is not live stock.
Patch, injection, extended-release, oral solution and combination
Separate exact productsCATAPRES-TTS, DURACLON, KAPVAY/JENLOGA/NEXICLON XR, JAVADIN and COMBIPRES are not merged into the immediate-release oral packs and do not establish a conversion.
Markets outside the United States
Local brand, strength, pack and supply are not establishedCheck the local regulator, current label and pack in hand item by item.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Is the pictured bottle the original CATAPRES product?
No. The image is a current TruPharma generic package panel under ANDA 070923. CATAPRES is shown only as the historical originator/RLD identity, and no generic image is presented as the original brand.
The tablet is scored. Can I split it or taper it myself?
Not from a score or arithmetic alone. The score only helps check exact appearance. Splitting, tapering and stopping depend on the prescription, exact product, individual context and rebound risk and require the responsible team or pharmacist.
Can oral clonidine be directly replaced with a CATAPRES-TTS patch?
The site cannot make that decision. The patch is labelled by nominal daily delivery from a one-week transdermal system, while oral tablets state milligrams per tablet. Release and time-course boundaries differ, so a shared ingredient or number cannot create a self-conversion.
Why should clonidine not be stopped abruptly?
The label records rebound pressure elevation, headache, nervousness/agitation and tremor after abrupt withdrawal, with rare life-threatening events. Missed medicine, vomiting, hospital admission or a nearly empty supply needs prompt prescriber or pharmacist contact rather than a web-generated catch-up or taper schedule.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.